SINGAPORE (Jan 9): German pharmaceutical giant Boehringer Ingelheim is acquiring assets and intellectual property from Singapore-based biotech company Enleofen Bio, in a step towards finding effective treatments for fibro-inflammatory diseases.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $4.99/month*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply